Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy
Titel:
Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy
Auteur:
Bazinet, Michel Pântea, Victor Placinta, Gheorghe Moscalu, Iurie Cebotarescu, Valentin Cojuhari, Lilia Jimbei, Pavlina Iarovoi, Liviu Smesnoi, Valentina Musteata, Tatiana Jucov, Alina Dittmer, Ulf Krawczyk, Adalbert Vaillant, Andrew